patent.fyi
Applications  /  US 2026/0355153
United States Patent Application Publication

US 2026/0355153 A1

Published
Nov 12, 2026
Filed
May 8, 2025
Earliest date on the face
May 8, 2025
Classification
A61K 31/381
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.4Alanine as the amino acid

What ifWhat if L-alanine served as the free amino acid in the stabilizer system?
Claim language“glycine at a concentration of 0.5% w/v”

L-alanine dissolves in the aqueous phase and contributes to the concentration of dissolved particles. An L-alanine concentration of about 5.9 mg/mL supplies the same molar concentration as 5 mg/mL glycine.

1.5Histidine for buffering

What ifWhat if L-histidine supplied the amino acid component used to resist pH drift?
Claim language“L-glutamic acid-L-lysine at a concentration of 0.3% w/v”

Dissolved L-histidine accepts or releases protons as the pH changes. A titration of the complete solution measures its contribution to buffer capacity at pH 3.8.

1.6Edetate binds trace metals

What ifWhat if disodium edetate bound trace metals in a formulation buffered by the remaining lactic acid and its conjugate base?
Claim language“citric acid at a concentration of 0.2% w/v”

Disodium edetate complexes dissolved iron and copper ions that catalyze oxidation. Lactic acid and lactate supply the buffer capacity around pH 3.8.

1.7Acetate supplies additional buffering

What ifWhat if acetic acid and sodium acetate supplied the weak acid and conjugate base for additional buffering?
Claim language“lactic acid at a concentration of 0.15% w/v”

Acetic acid and acetate exchange protons as acid or base enters the solution. The acid-to-salt ratio sets the pH, and their combined concentration determines how much they contribute to buffer capacity.

1.8Oxygen control through packaging

What ifWhat if low-oxygen filling and sealed glass ampoules controlled epinephrine oxidation?
Claim language“sodium metabisulfite at a concentration of 0.1% w/v”

Nitrogen sparging reduces dissolved oxygen before filling, and a nitrogen flush displaces air from the ampoule headspace. Flame-sealed glass limits oxygen entry during storage.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Veterinary injection simulator test fluid

A bench fixture for veterinary infiltration training pairs a silicone skin layer with an underlying transparent gel and a cartridge containing the described formulation. A syringe drives the solution through a replaceable cannula into the gel. A load cell records plunger force, and a camera records the spread of the injected fluid through the gel.

Component substitution

Mannitol as the tonicity agent

Mannitol replaces sodium chloride as the added tonicity agent in the aqueous formulation. The anesthetic salts, epinephrine, and stabilizer components retain their stated concentrations, with final pH adjusted to 3.8 ± 0.2. A freezing point osmometer measures the completed sodium chloride reference formulation first, then measures candidate mannitol formulations to establish the mannitol concentration that matches the reference osmolality.

Parameter or scale variation

Matched fill volumes for storage testing

A single batch supplies 0.50 mL, 1.00 mL, and 1.50 mL fills in identical 2 mL glass vials. Each vial uses the same stopper and crimp seal, and all fills have the same solute concentrations and initial pH. Replicate vials from each group are stored at 25 °C and sampled at 0, 7, and 28 days for epinephrine content and pH.

Combination with existing systems

Cartridge fixture with powered syringe drive

A dental cartridge containing the formulation fits into a bench fixture that couples its stopper to a motorized linear syringe drive. A pressure transducer sits between the cartridge outlet and a disposable cannula, with the cannula terminating in a gel test block. The drive advances the stopper at a programmed rate and records the outlet pressure and stopper travel throughout delivery.

Automated or data-driven variant

Automated ph adjustment of bulk solution

A stirred vessel uses a temperature-compensated pH probe and separate metering pumps for dilute acid and base. The controller reads the probe after each mixing interval and delivers a small correction when the stable reading falls outside 3.6 to 4.0. After the final volume adjustment, the controller logs the stabilized pH, solution temperature, and cumulative volume added by each pump.

Automated assay of cartridge storage samples

A liquid chromatograph with an autosampler analyzes aliquots taken from cartridges at scheduled storage intervals. A calibrated assay separates epinephrine from the local anesthetics and uses the epinephrine peak area to calculate concentration. Software associates each result with its batch, storage temperature, and elapsed storage time, then reports concentration as a percentage of the initial batch measurement.

Specific version of a part

Monohydrate corrected for potency

Crystalline lidocaine hydrochloride monohydrate supplies the lidocaine hydrochloride. The weighed amount accounts for the water of crystallization and the measured assay to deliver 20 mg of lidocaine hydrochloride per milliliter on an anhydrous basis.

Articaine from an aqueous concentrate

An aqueous concentrate contains 80 mg of articaine hydrochloride per milliliter. The concentrate supplies half the final batch volume and yields 40 mg/mL after final volume adjustment.

Water from vapor compression

A vapor-compression still evaporates feedwater and condenses the purified vapor as water for injection. The water dissolves the ingredients and brings the solution to its final volume.

Electrode guided ph adjustment

A calibrated glass electrode measures pH in the mixed solution. Small additions of dilute hydrochloric acid or sodium hydroxide bring the solution to pH 3.8, with a final acceptable range of 3.6 to 4.0.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2016/0113891 A1
Published
Apr 28, 2016
Filed
Jun 17, 2014
Class
A61K 31/137
Document BUS 11,826,347 B2
Published
Nov 28, 2023
Filed
Jul 21, 2021
Class
A61K 31/381
Claim 1
Document A
Document B
1.1(a) lidocaine hydrochloride at a concentration of 2% w/v (20 mg/mL)
For example, when lidocaine hydrochloride is mixed with adrenaline hydrochloride the buffering capacity of the lidocaine raises the pH of the intravenous admixtures above 5.5, the maximum necessary for stability of the adrenaline, to about 6.
A · US 2016/0113891 A1 · ¶ 9
1.2(b) articaine hydrochloride at a concentration of 4% w/v (40 mg/mL)
Commercially available injectable formulations include articaine hydrochloride (4%) with epinephrine in an amount of 1:1000,000 (0.01 mg/ml).
B · US 11,826,347 B2 · ¶ 57
1.3(c) epinephrine at a concentration of 1:200,000 w/v (0.005 mg/mL)
All test samples were prepared by adding adrenaline to a volumetric container to give a final concentration of 0.002 mg/ml.
A · US 2016/0113891 A1 · ¶ 73
1.4(d) a stabilizer system comprising: (i) glycine at a concentration of 0.5% w/v (5 mg/mL)
1.5(ii) L-glutamic acid-L-lysine at a concentration of 0.3% w/v (3 mg/mL)
1.6(iii) citric acid at a concentration of 0.2% w/v (2 mg/mL)
The concentration of citric acid in the injectable compositions of the present invention lies in the range of 0.1-100 mM, such as for example in the range of 1-50 mM.
A · US 2016/0113891 A1 · ¶ 35
The buffer complex can be obtained from the reaction mixture of boric acid, citric acid, or mixtures thereof, and a sugar alcohol, such as D-mannitol, sorbitol, and mixtures thereof.
B · US 11,826,347 B2 · ¶ 34
1.7(iv) lactic acid at a concentration of 0.15% w/v (1.5 mg/mL)
Next citric acid was added to give a final concentration of 0.5 mg/ml and then optionally a tonicity agent of either glucose (final concentration of 50 mg/ml), glycerol (final concentration of 25 mg/ml), lactic acid (final concentration of 16 mg/ml) or NaCl (final concentration of 9 mg/ml).
A · US 2016/0113891 A1 · ¶ 97
1.8(v) sodium metabisulfite at a concentration of 0.1% w/v (1 mg/mL)
The compositions of the present invention differ from the commercial products, which are on the market today, because the commercial products comprise both adrenaline and Na-metabisulfite as a preservative or antioxidant at much higher concentration levels.
A · US 2016/0113891 A1 · ¶ 31
1.9(e) sodium chloride at a concentration of 0.9% w/v (9 mg/mL)
TABLE 2 Formulation Composition Formulations (mg/g) composition Composition A B C D E F Articaine 80 80 80 80 80 80 HCl1 Sodium 9 7.5 6 4.5 — — Chloride Sodium — 1.37 1.37 4.5 1.373 1.373 Phosphate Monobasic Monohydrate Sodium — — — — — 1.413 Phosphate Dibasic Anhydrous HPMC 8.1 8.1 8.1 8.1 8.1 8.1 K100 Premium PEG400 4 4 4 4 4 4 Final pH 6.96 6.94 7.00 6.91 4.85 6.06 Viscosity 779-827 752-792 715-801 761-799 ~700 743-803 (cp) Osmolality 610 767 725 700 507 517 (mOsm/kg) 1Amo
B · US 11,826,347 B2 · ¶ 70
1.10(f) water for injection q.s. to 1 mL
The topical ophthalmic anesthetic composition in one embodiment is an aqueous mixture of at least about 7.5% w/v articaine, a buffer including a complex formed from boric acid and D-mannitol, sodium acetate, acetic acid, disodium edetate, and the balance water where the composition has a pH of pH 4.5 to about pH 5.0.
B · US 11,826,347 B2 · ¶ 15
1.11wherein the pH is adjusted to 3.8±0.2.
The solution pH was adjusted to either pH=3 or pH=4 by use of diluted NaOH/HCl
A · US 2016/0113891 A1 · ¶ 73

An empty cell means only that no passage was reproduced there.

Statements in these documents
The present invention relates to injectable pharmaceutical compositions showing improved storage stability.
A · US 2016/0113891 A1 · ¶ 1
Adrenaline oxidizes easily and darkens slowly on exposure to air and therefore instability of current adrenaline formulations constitute a major problem during storage if this issue is not properly addressed.
A · US 2016/0113891 A1 · ¶ 7
Exemplary implementations of certain embodiments of the disclosure provide methods for topically applying a topical anesthetic formulation, for example a drop, to achieve a high level of pars plana anesthesia, sufficient to permit intravitreal injection without undue discomfort to the patient.
B · US 11,826,347 B2 · ¶ 2
Currently available topical ophthalmic anesthetics perform on the external ocular surface but do not penetrate well enough to produce sufficient anesthesia of the internal aspect of the eye wall.
B · US 11,826,347 B2 · ¶ 6
Cite aspatent.fyi, US 2026/0355153 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355153/, SHA-256 b6dc86b370f4d07dc2c19ba746447422ed3fc37a13435b8c5be12d644b63ce9b
First published
Permanent addresshttps://patent.fyi/US20260355153/
Content fingerprint (SHA-256)b6dc86b370f4d07dc2c19ba746447422ed3fc37a13435b8c5be12d644b63ce9b
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi